New cancer vaccine slashes risk by 42 percent
Merck and Moderna reported that a personalized mRNA therapy for melanoma significantly lowered the chances of death or disease return in a major late-stage study.
By Aever Bundji ·
Melanoma patients treated with a new personalized mRNA vaccine alongside standard care saw a 42 percent reduction in the risk of death or cancer recurrence, according to results announced Thursday by Merck and Moderna. The findings from a late-stage trial represent a significant shift in how the deadliest form of skin cancer is managed. For patients who have already had their tumors surgically removed, this therapy offers a new option to help keep the disease from returning.
The companies stated they are already working with regulatory bodies to seek approval for the vaccine. Beyond the immediate impact on melanoma treatment, the success of this trial strengthens the argument that messenger RNA technology and individualized targeting strategies could define the next era of cancer therapy. It suggests that moving away from one-size-fits-all treatments toward customized medicine is a viable path for the industry.
Stéphane Bancel, the chief executive of Moderna, said in a statement that the company has long believed mRNA technology could enable cancer treatments matched specifically to each patient's tumor. He described the trial results as a defining moment for that vision, showing the potential of rethinking how medicines are developed. Bancel added that the data reinforces the conviction that mRNA has the capacity to fundamentally alter cancer treatment approaches.
The partners first reported in August that the vaccine had succeeded in the trial but delayed sharing specific details until the data could be presented at a scientific conference. That event, the European Society of Medical Oncology meeting in Madrid, Spain, is currently underway. The data was originally scheduled for presentation on Saturday. However, after an oncology news outlet reported the results ahead of the agreed-upon schedule, the companies released the top-line findings earlier than planned. The full dataset has been accepted for publication in the New England Journal of Medicine.
The Phase 3 trial involved 1,137 patients diagnosed with stage IIB through IV melanoma. All participants had undergone surgery to remove their tumors before entering the study. Researchers randomly assigned the patients to two groups in a two-to-one ratio. One group received the personalized mRNA vaccine in combination with standard treatment, while the other group received only the standard treatment.
The standard treatment used as the control in the study was Keytruda, an established monoclonal antibody therapy produced by Merck. The comparison between the combined therapy and the antibody alone provided the basis for the reported 42 percent reduction in risk. This approach highlights a collaborative model where pharmaceutical companies combine their existing platforms with emerging biotechnology to address complex disease challenges.
Source: Ars Technica
